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INVESTIGATION
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Zhenya Tang,*,1 Dorit S. Berlin,*,1 Lorraine Toji,* Gokce A. Toruner,† Christine Beiswanger,*
Shashikant Kulkarni,‡ Christa L. Martin,§,1 Beverly S. Emanuel,** Michael Christman,*
and Norman P. Gerry*,2
*Coriell Institute for Medical Research, Camden, New Jersey 08103, †Institute of Genomic Medicine, UMDNJ-NJ Medical
School, Newark, New Jersey 07103, ‡Cytogenomics and Molecular Pathology, Department of Pathology and
Immunology, Washington University School of Medicine, St. Louis, Missouri 63110, §Department of Human Genetics,
Emory University, Atlanta, Georgia 30322, and **Department of Pediatrics, Children’s Hospital of Philadelphia, and the
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ABSTRACT The Human Genetic Cell Repository sponsored by the National Institute of General Medical
Sciences (NIGMS) contains more than 11,000 cell lines and DNA samples collected from numerous
individuals. All of these cell lines and DNA samples are categorized into several collections representing
a variety of disease states, chromosomal abnormalities, heritable diseases, distinct human populations, and
apparently healthy individuals. Many of these cell lines have previously been studied with detailed
conventional cytogenetic analyses, including G-banded karyotyping and ﬂuorescence in situ hybridization.
This work was conducted by investigators at submitting institutions and scientists at Coriell Institute for
Medical Research, where the NIGMS Repository is hosted. Recently, approximately 900 cell lines, mostly
chosen from the Chromosomal Aberrations and Heritable Diseases collections, have been further charac-
terized in detail at the Coriell Institute using the Affymetrix Genome-Wide Human SNP Array 6.0 to detect
copy number variations and copy number neutral loss of heterozygosity. A database containing detailed
cytogenetic and genomic information for these cell lines has been constructed and is freely available
through several sources, such as the NIGMS Repository website and the University of California at Santa
Cruz Genome Browser. As additional cell lines are analyzed and subsequently added into it, the database








The National Institute of General Medical Sciences (NIGMS) estab-
lished the Human Genetic Cell Repository (NIGMS Repository)
40 years ago. The NIGMS Repository is maintained by the Coriell
Institute for Medical Research (Coriell Institute) in Camden, New
Jersey. To date, more than 11,000 unique samples have been donated
by different individuals for the production of cell lines and genomic
DNA. These samples are distributed among several collections and
represent a variety of chromosomal abnormalities, heritable diseases,
numerous distinct human populations, and apparently healthy indi-
viduals. All of the samples distributed through the NIGMS Repository
have been intensively analyzed by the investigators who submitted the
samples originally and/or scientists at the Coriell Institute. As part of
its mission to update/supplement the phenotypic information associ-
ated with the NIGMS Repository samples, the Coriell Institute utilizes
the latest cytogenetic and genomic techniques to analyze samples.
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Recently, microarray-based genomic copy number analysis, also
called chromosomal microarray analysis (CMA), has become a widely
performed genomic diagnostic test (Emanuel and Saitta 2007; Lee
et al. 2007; Stankiewicz and Beaudet 2007). CMA has several potential
advantages over classical cytogenetic techniques, including high reso-
lution, time-savings/cost-effectiveness, and de novo analysis without
previous phenotypic information. In 2007, the annual volume of CMA
tests performed clinically was more than 10,000 in the United States
alone (Bejjani and Shaffer 2006; Cheung et al., 2005; Lee et al. 2007).
In 2010, a panel of experts from International Standard Cytogenomic
Array Consortium recommended that CMA testing be applied as the
ﬁrst-tier clinical diagnostic test for individuals with developmental
disabilities/intellectual disabilities, autism spectrum disorders, congen-
ital anomalies, or dysmorphic features in place of conventional G-
banded karyotype analysis (Miller et al. 2010). About the same time,
the American College of Medical Genetics and Genomics (ACMG)
has issued a series of statement and practice guidelines regarding the
clinical use of CMA, including design and performance expectation of
the CMA platforms, interpretation, and reporting of the CMA results
(Kearney et al. 2011a,b; Manning and Hudgins 2010). Up to date,
a large number of laboratories have already adapted CMA testing in
clinical diagnostics, and many more are interested in applying it as
part of standard of care in the near future. Many clinical laboratories
and research institutes use NIGMS Repository cell lines and/or DNA
samples, particularly samples from the Chromosomal Aberrations and
Heritable Diseases collections, as standards or reference materials to
develop and validate their CMA assays. To better serve the scientiﬁc
community, a CMA assay, the Affymetrix Genome-Wide Human
SNP Array 6.0 (SNP Array 6.0; Affymetrix, Santa Clara, CA), has
been used to further characterize the NIGMS Repository cell lines.
To date, approximately 900 cell lines have been analyzed on the SNP
Array 6.0 for copy number variations (CNVs) and long contiguous
stretches of homozygosity or absence of heterozygosity (AOH), which
is also referred to as copy number-neutral loss of heterozygosity as
labeled in some ﬁgures generated by the ChAS software. We describe
herein the construction of a database containing detailed cytogenetic
and genomic information for all of these cell lines.
COMPOSITION OF THE DATASET
In 2010, 716 samples derived from 697 individuals from NIGMS
Repository collections were analyzed for CNVs using the SNP
Array 6.0. The majority of these samples were chosen from the
Figure 1 An example of a case presentation in the NIGMS Repository online catalog (cell line GM00657). The red arrow indicates the complete
ISCN nomenclature of this cell line. The green arrow indicates links to representative images. Other information, e.g., phenotype data, publi-
cation, etc., can be accessed by clicking on related icons on the webpage.
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Chromosomal Aberrations and Heritable Diseases collections. The
resulting data, intensity data ﬁles (CEL ﬁles), and genotype data ﬁles
(CHP ﬁles), along with a limited set of phenotypic information (e.g.,
gender, age at time of sample collection, and name of diagnosed
disease or category of aberration), were deposited in the Database
of Genotypes and Phenotypes (dbGaP) under the project name
“Genotyping NIGMS Chromosomal Aberration and Inherited Dis-
order Samples” (Study Accession ID: phs000269.v1.p1). Access to
the data is available through dbGaP’s Authorized Access mechanism
(https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login). Recently, more
than 200 additional NIGMS Repository cell lines have been analyzed
with the SNP Array 6.0. A large fraction of these additional lines are
newly recruited samples from submitters around the world and repre-
sent new collections for diseases or disease spectrums not previously
held by the Repository, e.g., monosomy 1p36 syndrome, congenital
muscular dystrophies, and chromosome 15q11-q13 duplication syn-
drome, among others. The new CEL ﬁles generated from these new
cell lines will be available in the dbGaP as well.
All data ﬁles (CEL ﬁles) were analyzed in Genotyping Console
software (Affymetrix). The Contrast QC and MAPD metrics generated
by the software were used for quality control purposes. Values of 0.4
and 0.35, respectively, were used as cutoffs for high-quality data. For
reporting purposes, the copy number and AOH ﬁles (CNCHP ﬁles)
produced by the Genotyping Console software were subsequently
analyzed using Chromosome Analysis Suite (ChAS) software (Affyme-
trix). All CEL ﬁles have been re-analyzed with Nexus 6.0 software
(BioDiscovery, El Segundo, CA) with the same parameters described
below to conﬁrm all the CNV calls included in this dataset.
The parameters used to call a CNV (loss or gain) in the majority of
the cell lines were a segment size $100 kb consisting of at least 10
contiguous markers (CNV-only probes) and a conﬁdence score of 95.
The minimum parameters used to call a region of AOHwere a segment
size $5 Mb consisting of at least 10 contiguous markers (SNP-only
probes) and a conﬁdence score of 95. In addition to analysis using the
above default parameters, some samples with a known small patho-
genic deletion or duplication previously detected by other methods
(e.g., polymerase chain reaction, multiplex ligation-dependent probe
ampliﬁcation, DNA sequencing) were reanalyzed with new parameters
(e.g., $ 25 kb consisting of at least 10 contiguous markers and a con-
ﬁdence score of 95 for CNVs) that would permit detection of segments
of ,100 kb. To minimize the possibility of missing a potential path-
ogenic abnormality, all CNVs ($25 kb) involving one or more of the
genes described in the Online Mendelian Inheritance in Man (OMIM)
Morbid Map were reported, even when, according to the clinical in-
formation, they were detected in apparently healthy individuals. This is
necessary to point out that some of the CNVs, many of which have
a size of 25 2100 kb but involve one or more OMIM Morbid Map
genes, may not have been further conﬁrmed by other methods at
Coriell Institute. The primary goal of this analysis was to extract as
much copy number information as possible from each cell line, regard-
less of clinical pathogenicity. Therefore, the parameters used to gener-
ate the database would not necessarily be suitable for clinical diagnostic
purposes. Clinical scientists who wish to reanalyze the CEL ﬁles should
refer to the guidelines issued by the ACMG for the appropriate param-
eters to be used (Kearney et al. 2011a,b; Manning and Hudgins 2010).
All CNV as well as AOH calls were manually checked, whereas the
information of probe coverage, allele difference, and segmental duplica-
tion at the region where a call is primarily made were considered. Finally,
of 879 cell lines at this moment, a total of 6588 CNV calls with an
average size of 285 kb covered by an average of 1617 CNV markers and
202 AOH calls (no including the X chromosome) (Rehder et al. 2013)
with an average size of 11 Mb covered by an average of 3014 SNP-only
markers has been made (data not included). Detailed information on
each cell line, including CMA results, is available in the NIGMS Re-
pository online catalog and can be openly accessed. The CMA results
have been presented in three ways.
Figure 2 Example of G-banded karyo-
type analysis of GM00657. Red arrows
indicate two abnormal chromosomes,
7 and 18, respectively. Based on the
karyotype image, this case was orig-
inally considered as a t(7;18) with
potentially microdeletion on chromo-
somes 7, 18, or both. No involvement
of the chromosome 8 has been docu-
mented at that time.
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First, critical CNVs in each cell line have been reported using the
International System for Human Cytogenetic Nomenclature (ISCN).
The term “critical CNVs” refers to all chromosomal abnormalities
detected or conﬁrmed by G-banded karyotype and/or ﬂuorescence
in situ hybridization (FISH) analyses, as well as those subtle CNVs
($25 kb) which have not been detected by conventional methods, but
involve one or more OMIM genes as outlined previously. AOH has
been detected in many cell lines in this dataset. Examples of AOH in
the dataset include AOH affecting one or more segments of a chro-
mosome; a whole chromosome or even the whole genome of a cell
line. In general, the clinical signiﬁcance of the majority of AOH,
especially the AOH only affecting chromosomal segment(s) detected
in this study, is unknown. The detected AOH regions have not been
further conﬁrmed by other methods, such as methylation testing.
Therefore, the majority of AOH information has not been integrated
into the ISCN reports except in special cases, e.g., GM01225, in which
AOH was detected on 14 segments involving 9 different chromosomes
(no including the X chromosome) (Rehder et al. 2013) of a total size
of about 280 Mb (Figure 6); GM11496 with a diagnosis of uniparental
disomy of chromosome 7, UPD (7); GM20409 with a diagnosis of
UPD (15); GM07489 and GM16810, in which AOH was detected on
the whole genome; and other Prader-Willi syndrome (PWS) and
Angelman syndrome cell lines, where the UPD of 15q11.2-q13 has
been conﬁrmed by submitters using a methylation assay previously.
To avoid misleading investigators, unconﬁrmed AOH information is
not disclosed at this moment, but detailed AOH information of each
cell line can be provided at individual request. Investigators are en-
couraged and expected to exchange their own CMA test results on cell
lines that they did or are going to choose from this dataset with
scientists at Coriell Institute so that a set of conﬁrmed AOH can be
published in our online catalog and become accessible to the commu-
nity in the near future.
Through the aforementioned NIGMS Repository online catalog,
researchers can ﬁnd all relevant genomic analyses for each cell line.
Within the ISCN entry on the Overview tab, all results from G-banded
karyotype, FISH, and/or CMA analyses have been presented accord-
ing to the ISCN 2013 guidelines (Figure 1, cell line GM00657 as an
example). Representative karyotype and FISH images demonstrating
chromosomal abnormalities detected in a cell line can be obtained by
clicking on the Images tab (Figure 2 and Figure 3, cell line GM00657
as an example). One or more images of CMA analysis for each cell
line of this dataset may be available and accessible, depending on the
numbers of chromosomes and loci affected in the cell line. Typical
images available include a “Karyoview,” presenting a diagram of all
CNVs (Figure 4, cell line GM00657 as an example) and AOH (Figure
6A, cell line GM01225 as an example) detected in the whole genome,
and one or more images of individual chromosomes (“chromosomal
view or detail view”) presenting speciﬁc abnormalities (Figure 5, cell
line GM00657 as an example and Figure 6B, cell line GM01225 as an
example).
Second, a spreadsheet including sample ID and short and long
ISCN nomenclature describing the chromosomal abnormalities of all
cell lines in this database is available both online and as a supplement
to this report (see Supporting Information, Table S1). Users of the
data, especially those comparing it with results obtained by using
different platforms than the SNP Array 6.0, are reminded that many
factors, including the probe density, analysis parameters, and genome
build/annotation ﬁles used, will impact the ﬁnal results.
Third, a total number of 957 critical CNVs (loss or gain) from 602
cell lines has been integrated into a custom track within the University
of California at Santa Cruz Genome Browser so far, and they are
Figure 3 Examples of FISH studies of GM00657. (A) Subtelomere
probes for long arm of chromosome 8 (8q) (D8S1925, green color) and
long arm of chromosome 18 (18qtel) (D18S1380, red color) were
applied to this study. Green hybridization signals for 8qtel have been
detected in two normal chromosomes 8 (labeled as chr8) as well as the
abnormal chromosome 18, labeled as der(18). This extra green
hybridization signal on der(18)indicates a possible gain of 8qtel as
well as a structural rearrangement between chromosomes 8 and 18.
Red hybridization signals for 18qtel have been detected in the normal
chromosome 18 (labeled as chr18) as well as the abnormal chromo-
some 7, labeled as der(7), but not in the abnormal der(18), indicating
possibly no loss of 18qtel, but instead, a translocation involving
chromosomes 7 and 18. (B) Whole chromosome paint 18 was applied
in this study. In addition to both normal and abnormal chromosomes
18 (labeled as chr18 and der(18), respectively), the distal q arm of the
abnormal chromosome 7, der(7), has been painted, further conﬁrming
a structural rearrangement between chromosomes 7 and 18, most
likely causing a deletion of terminal q arm of the der(7).
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categorized in the group “Phenotype and Disease Associations” under
the name “Coriell CNVs.” This information is readily accessible and
searchable by all research scientists.
APPLICATIONS OF THIS DATABASE
Research of interest
The samples in the NIGMS Repository have been used extensively by
scientists around the world for a wide variety of research purposes.
Publications that use NIGMS Repository samples continually appear
in the scientiﬁc literature. A list of recent publications can be found on
the NIGMS Repository website. Although many investigators may
have performed copy number analysis on individual samples of the
NIGMS Repository and shared their ﬁndings with the Coriell
Institute, this database represents the ﬁrst concerted effort to generate
and curate genome-wide copy number data for a large number of
samples. Scientists may ﬁnd numerous mutations in this database that
have not been revealed before. For example, a preliminary analysis of
the CMA data from approximate 700 cell lines in this database (Z.
Tang, D. Berlin and N. Gerry, unpublished data) has resulted in the
annotation of 1120 clinically pathogenic and 4470 most likely benign
or uncertain clinical signiﬁcance CNVs (gain or loss) involving all
autosomal and sex chromosomes, according to the ACMG guidelines
for interpretation and reporting of the CMA results (Kearney et al.
2011b). In addition, 165 regions of AOH $5 Mb involving all chro-
mosomes except chromosome 20 were detected. More interestingly,
Figure 4 Example of Karyoview of
CMA analysis of GM00657. The karyo-
view presents a diagram of all CNVs
(red bar for loss; blue bar for gain) and
AOH (purple bar, if present) on the
whole genome of the cell line tested.
The size of each bar usually reﬂects the
size of the CNV and/or AOH propor-
tionally. The major CNVs in this case
are the loss of distal 7q and the gain of
distal 8q. Although the chromosomes
18 are involved in structural rearrange-
ment with both chromosomes 7 and 8
as detected by karyotype and FISH
analyses, but CMA analysis did not
detect a CNV on the chromosomes 18.
Figure 5 Example of detail or chro-
mosomal view of CMA analysis of
GM00657, presenting the speciﬁc ab-
normalities at chromosomal levels. (A)
Detail view of chromosome 7 with an
obvious deletion of distal 7q; (B) Detail
view of chromosome 8 with an obvious
gain of distal 8q. In addition to Copy
Number State, Allele Difference, Smooth
Signals, and OMIM genes shown here,
other information, e.g., Log2 ratio,
AOH state, FISH probes, segmental
duplication, non-OMIM genes, etc.,
can be presented in the detail view
as well.
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approximately 400 of the pathogenic CNVs and almost all of the
benign or uncertain clinical signiﬁcance CNVs had not been previ-
ously detected by G-banded karyotype or FISH analysis. Furthermore,
the CMA analysis has revealed the AOH status for the ﬁrst time in
most of these cell lines. Therefore, this database provides investigators
with detailed cytogenetic and genomic information of each cell line.
It can be used as a supplement to existing phenotypic data in the
NIGMS Repository online catalog as well as the scientiﬁc literature.
Validation for CMA assays
Although the CMA assay has been recommended as the ﬁrst-tier
clinical diagnostic test for individuals with developmental disabilities
or congenital anomalies, the results can vary between individual
laboratories (Bejjani and Shaffer 2006; Lee et al. 2007; Kaminsky et al.
2011; Riggs et al. 2012). Some of the sources of this variation include:
(1) commercial CMA platforms of different design and content, (2)
analysis parameters applied to the raw data to determine the presence
of CNVs and/or AOH (e.g., the minimum number of base pairs in-
volved and the minimum number of associated markers), and (3)
methods used to validate the CMA assay (e.g., number and types of
specimens and their genetic and genomic background). As a result,
the development of reference materials that can be widely used for
CMA validation has become necessary. The Genetic Testing Reference
Materials Coordination Program, led by the Center for Disease Con-
trol and Prevention, has been focusing on creating a genomic DNA
reference material panel of at least 96 extensively analyzed cell lines
containing a broad range of chromosomal abnormalities, e.g., micro-
deletions and microduplications, subtelomeric abnormalities, UPD, as
well as other genetic variations. To date, as part of the Genetic Testing
Reference Materials Coordination Program, a panel of 45 cell lines, all
chosen from the NIGMS Repository, has been tested with several
commercial CMA platforms by their producers (L. Kalman, H. Kearney,
L. Conlin, L. Toji, D. Berlin, C. Carmack, J. Gastier-Foster, S. B. Fulmer-
Smentek, N. Gerry, L. Jennings, V. Jobanputra, C. Lee, J Leonard,
B. Levy, C. Shaw, R. Shippy, S. South, N. Spinner, D. J. Stavropoulos,
Z. Tang, H. VanSteenhouse, E. Winn-Deen, D. Wolff, A. Yesupriya,
I. Znoyko, and S. Kulkarni). Development of characterized genomic
DNA reference material panels for clinical chromosomal microarrays.
Presented at the 12th International Congress of Human Genetics/61st
Annual Meeting of The American Society of Human Genetics, October
12, 2011, Montreal, Canada). The resulting data have been analyzed by
several Cytogenetics experts from various institutes. Currently, this
panel of 45 cell lines (“CNVPANEL01”) (Table S2) has been recom-
mended to be applied for developing and validating a CMA assay. It is
speciﬁcally listed and accessible on the NIGMS Repository website. All
the other cell lines documented in this database serve as the pool from
which the rest of the specimens for the complete CNV panel will be
chosen. This database covers the majority of the most commonly
encountered chromosomal conditions in clinical practice, as well as
many rarely seen chromosomal abnormalities. Scientists are encour-
aged to use samples from the CNVPANEL01 or any other cell lines in
the database to validate their own CMA assays.
Reference material panel
Many laboratories focus their testing on a certain disease or disease
spectrum. Under these circumstances, a CMA assay is expected to
Figure 6 Examples of images of copy
number neutral AOH presented in the
online catalog. (A) Karyoview of the
cell line GM01225 showing AOH (pur-
ple bars next to each chromosome
ideogram) and CNVs detected. (B) Detail
view of chromosome 12 (Chr12) indicat-
ing AOH involving three segments
through the whole chromosomes 12.
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be capable of detecting as many chromosomal conditions related to
the disease or disease spectrum as possible. This database can assist
laboratories in identifying relevant samples for several diseases and
disease spectrums. For example, there are currently 23 cell lines
from individuals with PWS and their family members included
in this database. The spectrum of variants contained in this subset
of cell lines includes microdeletions of various sizes within the
15q11.2-q13 region, as well as examples of both isodisomic and
heterodisomic (previously conﬁrmed with methylation tests by the
submitters and investigators who used the cell lines) maternal UPD
(matUPD) (Z. Tang, D. Berlin, M. Wineburg, A. MacMillan,
D. Altamuro, L. Toji, C. Beiswanger, S. Madore, N. Gerry. Mechanism-
based Analysis of Human Cell Lines of Prader-Willi Syndrome.
Presented at the 62nd Annual Meeting of The American Society of
Human Genetics, Date, November 8, 2012 in San Francisco, CA). Many
other cell lines in the database also have one or more chromosomal
abnormalities involving chromosome 15. Therefore, these cell lines can
also be used to build a reference material panel to validate a CMA assay
with emphasis on PWS and/or abnormalities on chromosome 15. Other
examples of large subsets of samples in the database include, but are not
limited to, monosomy 1p36 syndrome, Duchenne muscular dystrophy,
Cri-Du-Chat syndrome, and Williams-Beuren syndrome. Many cell
lines also have exhibited mosaic karyotypes of different degrees during
G-banded karyotype analysis. The mosaic status has also detected
by the SNP array 6.0 in some cell lines (Z. Tang, N. Gerry,
D. Berlin, A. MacMillan, M. Wineburg, B. A. Frederick, L. Toji,
G. A. Toruner, C. Beiswanger. Analysis of 24 Cell Lines of
Mosaicism by the Affymetrix Genome-Wide Human SNP Array 6.0.
Presented at the 12th International Congress of Human Genetics/61st
Annual Meeting of The American Society of Human Genetics, October
12, 2011, Montreal, Canada). These cell lines are good resources to test
the ability of a platform to detect mosaic karyotypes.
Feedback
All investigators are encouraged to provide feedback regarding
ﬁndings they obtained from analyzing any of the cell lines included
in the database, regardless of the assay or platforms used, so that more
information about each cell line can be added to the database and
shared with the research community. Feedback can be relayed either
through the web-based customer services forms or through personal
communication with scientists at Coriell Institute by sending an e-mail
to NIGMS@coriell.org.
In summary, a database containing genomic information for
approximately 900 cell lines, which are mostly chosen from the
Chromosomal Aberrations Collection and Heritable Diseases Collec-
tion of the NIGMS repository and intensively analyzed by karyotype,
FISH, and CMA assays at the Coriell Institute, has been constructed.
We believe that this database will serve the clinical and research
communities with cell lines and/or DNA samples containing detailed
genomic information. This database will be maintained dynamically
as additional cell lines are analyzed and subsequently added.
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